Sandoz Group AG (SDZXF)
- Previous Close
42.37 - Open
36.07 - Bid 41.75 x 36100
- Ask 42.61 x 46000
- Day's Range
36.07 - 36.07 - 52 Week Range
25.75 - 44.15 - Volume
320 - Avg. Volume
276 - Market Cap (intraday)
18.939B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.02 - Earnings Date Aug 8, 2024
- Forward Dividend & Yield 0.50 (1.20%)
- Ex-Dividend Date May 3, 2024
- 1y Target Est
--
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
www.sandoz.com22,633
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SDZXF
View More
Performance Overview: SDZXF
Trailing total returns as of 10/10/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SDZXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SDZXF
View MoreValuation Measures
Market Cap
19.01B
Enterprise Value
18.60B
Trailing P/E
207.78
Forward P/E
11.26
PEG Ratio (5yr expected)
0.20
Price/Sales (ttm)
1.76
Price/Book (mrq)
2.13
Enterprise Value/Revenue
1.84
Enterprise Value/EBITDA
24.67
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.08%
Return on Assets (ttm)
0.81%
Return on Equity (ttm)
-0.06%
Revenue (ttm)
10.11B
Net Income Avi to Common (ttm)
-8M
Diluted EPS (ttm)
-0.02
Balance Sheet and Cash Flow
Total Cash (mrq)
701M
Total Debt/Equity (mrq)
53.12%
Levered Free Cash Flow (ttm)
1.62B
Company Insights: SDZXF
SDZXF does not have Company Insights